IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Bladder cancer

July 2019

IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA

IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer.

Read the press release here (in swedish)

IDL Biotech is making progress in Africa

IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company delivers TUBEX® TF.

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

IDL Biotech

Skip this intro